8-K: Tempest Therapeutics Reports Year-End 2024 Financial Results and Provides Business Update

Tempest Therapeutics announced its year-end 2024 financial results, highlighting progress with Amezalpat and TPST-1495, along with key regulatory designations and a collaboration with Roche.

Summary

• Tempest Therapeutics reported its financial results for the year ended December 31, 2024.
• The company ended the year with $30.3 million in cash and cash equivalents, compared to $39.2 million at the end of 2023.
• The decrease in cash was primarily due to operating activities, offset by $28.6 million in proceeds from an at-the-market offering program.
• Net loss for the year was $41.8 million, or $1.50 per share, compared to a net loss of $29.5 million, or $1.91 per share, in 2023.
• Research and development expenses increased to $28.5 million from $17.5 million in the previous year, driven by costs related to the Phase 3 trial of amezalpat.
• General and administrative expenses increased to $13.6 million from $11.7 million, primarily due to higher stock-based compensation and legal/consulting expenses.
• Amezalpat received Orphan Drug and Fast Track designations from the FDA for the treatment of Hepatocellular Carcinoma (HCC).
• Tempest announced an agreement with Roche to support the advancement of Amezalpat combination therapy into a first-line HCC pivotal trial.
• The FDA issued a Study May Proceed letter for the Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis (FAP).
• Data from the TPST-1495 Phase 2 trial is expected in 2026.
• The company plans to advance Amezalpat into a registrational study in first-line liver cancer patients, contingent on securing additional resources.
• The company plans to advance TPST-1495 into a Phase 2 study in patients with FAP under the auspices of the Cancer Prevention Clinical Trials Network and funded by the National Cancer Institute (NCI) Division of Cancer Prevention in 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a larger net loss and decreased cash reserves, it also achieved key regulatory milestones, secured a collaboration with Roche, and reported positive clinical data for Amezalpat. The need for additional resources to advance Amezalpat introduces some uncertainty.

Positives

• Amezalpat received Orphan Drug and Fast Track designations from the FDA, potentially expediting its development and approval.
• The agreement with Roche to advance Amezalpat into a Phase 3 trial validates its potential and provides support for its development.
• The FDA's Study May Proceed letter for TPST-1495 allows the company to move forward with its Phase 2 trial for FAP.
• Amezalpat delivered a six-month improvement in median overall survival (OS) when combined with atezolizumab and bevacizumab in comparison to atezolizumab and bevacizumab alone, the standard of care, in the first-line treatment of patients with unresectable or metastatic HCC.
• The company secured $28.6 million through an at-the-market offering program, bolstering its financial position.

Negatives

• The company experienced a net loss of $41.8 million for the year, an increase from the $29.5 million loss in the previous year.
• Cash reserves decreased from $39.2 million to $30.3 million, indicating a need for additional funding to support ongoing clinical trials and operations.
• Increased research and development expenses contributed to the higher net loss, reflecting the costs associated with advancing clinical programs.

Risks

• The company's ability to advance Amezalpat into a registrational study is contingent on obtaining additional resources, which may be challenging in difficult capital markets.
• Clinical trials are subject to inherent risks, including unexpected safety or efficacy data, slower than expected enrollment rates, and changes in the regulatory environment.
• The company faces competition from other companies developing cancer therapeutics, which could impact its ability to successfully commercialize its product candidates.
• Unexpected litigation or other disputes could negatively impact the company's financial condition and operations.

Future Outlook

The company plans to advance Amezalpat into a registrational study in first-line liver cancer patients, subject to obtaining additional resources, and to advance TPST-1495 into a Phase 2 study in patients with FAP in 2025, with data expected in 2026.

Management Comments

• 2024 was another year filled with significant progress and milestone achievements that position Tempest for a successful future, said Stephen Brady, president and chief executive officer of Tempest.
• Despite challenging capital markets, our lean team excelled, reporting key OS data from the ongoing randomized Phase 2 trial of amezalpat in first-line hepatocellular carcinoma.
• Our focus remains on execution with excellence while securing the resources necessary to drive these promising drug candidates forward.

Industry Context

The announcement highlights Tempest's progress in the competitive oncology space, particularly in liver cancer and FAP. The collaboration with Roche is a significant endorsement of Amezalpat's potential in combination therapy. The receipt of Orphan Drug and Fast Track designations underscores the unmet need in these indications.

Comparison to Industry Standards

• The six-month improvement in median overall survival (OS) with Amezalpat in combination with atezolizumab and bevacizumab is a clinically meaningful result in the context of first-line HCC treatment.
• Companies like Exelixis (Cabometyx) and Bayer (Sorafenib) have established standards of care in HCC, and Amezalpat's potential to improve upon these standards is noteworthy.
• The development of TPST-1495 for FAP addresses a rare genetic condition, aligning with industry trends towards personalized medicine and targeted therapies.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and clinical updates will impact shareholder value and investment decisions.
• Employees: The company's progress and financial stability affect employee morale and job security.
• Patients: The development of new cancer therapies has the potential to improve patient outcomes and quality of life.
• Partners: The collaboration with Roche strengthens the company's position and provides opportunities for future partnerships.

Next Steps

• Advance Amezalpat into a registrational study in first-line liver cancer patients, subject to obtaining additional resources.
• Advance TPST-1495 into a Phase 2 study in patients with FAP in 2025, with data expected in 2026.

Key Dates

Keywords

Tempest Therapeutics, Amezalpat, TPST-1120, TPST-1495, Hepatocellular Carcinoma, Familial Adenomatous Polyposis, HCC, FAP, Clinical Trial, Financial Results, Orphan Drug Designation, Fast Track Designation, Roche, FDA